课题基金 / 基金详情

SYK and ZAP70 kinases in lymphocyte selection

SYK and ZAP70 kinases in lymphocyte selection
SYK 和 ZAP70 激酶在淋巴细胞选择中的作用
批准号:
10557882
负责人:
Eric Meffre
金额:
$61.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-02-01 至 2027-01-31

项目摘要

项目成果

Eric Meffre的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 虽然B细胞承受着消除自身反应和癌前克隆的巨大选择压力, 我们将SYK确定为中央激酶,以设定负选择的阈值。SYK及其高级化 同源亲缘ZAP70启动B细胞受体和T细胞受体信号转导 分别为T淋巴细胞。尽管这两个激酶几乎完全相同,并且服务类似 功能,它们在B细胞和T细胞中的表达在整个进化过程中是严格分离的。鉴于 分离两种蛋白的原因不明,Syk和ZAP70的异常共表达 以前报道过B细胞慢性淋巴细胞白血病(CLL)和外周T细胞淋巴瘤 (PTCL)。我们的研究小组最近证实,ZAP70的异常表达是Pre-Pre的常见特征。 生发中心(GC)B细胞恶性肿瘤(B-ALL、CLL、MCL;SADRAS等人,Mol Cell 2021)。在遗传方面 B-ALL和B-CLL小鼠模型,诱导共表达ZAP70加速疾病发病,而 基因缺失阻碍了恶性转化。同样,ZAP70的诱导表达在 早期B细胞发育颠覆自身反应性B细胞负选择促进弥漫性 自身抗体的产生。 从机制上讲,ZAP70与SYK竞争,对SYK依赖的SYK产生显性负向作用 钙离子--信号转导。通过占用而不是磷酸化BLNK、BTK和PLC2底物 通过钙信号转导,ZAP70显著降低了自主钙振荡的频率。快地 在SYK(4.5 MHz)单独存在的情况下,振荡由NFATC1解码,并导致无能和 细胞死亡。相反,在ZAP70(0.25 MHz)存在下,缓慢的钙振荡促进选择性 激活核因子-B和B细胞的存活和增殖。 我们在这里测试了一个中心假设,即B细胞感知A细胞下游的病理性信号 自身反应性bcr或通过SYK依赖的高频钙离子-转化癌基因- 震荡。在高频下,钙离子振荡激活NFATC1启动B细胞无能和克隆性 删除。相反,ZAP70可减缓钙离子振荡以激活核因子-B,而不是NFATC1. 使自身反应性和癌前B细胞克隆持续存在,并最终导致自身免疫 疾病或GC前B细胞恶性肿瘤。 我们提出三个目标:(1)阐明ZAP70延缓SYK- 依赖的高频钙振荡,以(2)确定ZAP70的共表达如何颠覆 自身免疫性疾病中自身反应性B细胞的阴性选择和(3)揭示ZAP70是如何 使癌前B细胞发生致癌信号和明显的恶变。
英文摘要
ABSTRACT While B-cells are under intense selective pressure to eliminate autoreactive and pre-malignant clones, we identified SYK as central kinase to set the thresholds for negative selection. SYK and its highly homologous relative ZAP70 initiate B-cell receptor (BCR) and T-cell receptor (TCR) signaling in B- and T-lymphocytes, respectively. Even though the two kinases are almost identical and serve analogous functions, their expression in B- and T-cells is strictly segregated throughout evolution. Whereas the reason for separation of the two kinases is not known, aberrant coexpression of Syk and Zap70 was previously reported in B-cell chronic lymphocytic leukemia (CLL) and in peripheral T-cell lymphoma (PTCL). Our group recently demonstrated that aberrant ZAP70 expression is a common feature in pre- germinal center (GC) B-cell malignancies (B-ALL, CLL, MCL; Sadras et al., Mol Cell 2021). In genetic mouse models for B-ALL and B-CLL, inducible coexpression of Zap70 accelerated disease onset, while genetic deletion impaired malignant transformation. Likewise, inducible expression of Zap70 during early B-cell development subverted negative selection of autoreactive B-cells to promote pervasive autoantibody production. Mechanistically, ZAP70 competes with SYK and exerts a dominant-negative effect on SYK-dependent Ca2+-signaling. By occupying but not phosphorylating BLNK, BTK and PLC2 substrates upstream of calcium signaling, ZAP70 dramatically reduces the frequency of autonomous Ca2+-oscillations. Fast oscillations in the sole presence of SYK (4.5 mHz) are decoded by NFATC1 and result in anergy and cell death. In contrast, slow Ca2+-oscillations in the presence of ZAP70 (0.25 mHz) promote selective activation of NF-B and B-cell survival and proliferation. We test here the central hypothesis that B-cells sense pathological signaling downstream of an autoreactive BCR or a transforming oncogene through SYK-dependent high-frequency Ca2+- oscillations. At high frequencies, Ca2+-oscillations activate NFATC1 to initiate B-cell anergy and clonal deletion. Conversely, ZAP70 slows down Ca2+-oscillations to activate NF-B instead of NFATC1 and enables autoreactive and premalignant B-cell clones to persist and eventually give rise to autoimmune disease or pre-GC B-cell malignancies. We are proposing three Aims to (1) elucidate the mechanisms by which ZAP70 slows down SYK- dependent high-frequency Ca2+-oscillations, to (2) determine how coexpression of ZAP70 subverts negative selection of autoreactive B-cells in autoimmune disease and (3) to uncover how ZAP70 enables oncogenic signaling and overt malignant transformation of pre-malignant B-cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the immunology of autoantibody formation and function in COVID-19
  • 批准号:
    10639707
  • 项目类别:
  • 资助金额:
    $75.07万
  • 财政年份:
    2023
  • 负责人:
    Eric Meffre
  • 依托单位:
SYK and ZAP70 kinases in lymphocyte selection
  • 批准号:
    10467215
  • 项目类别:
  • 资助金额:
    $61.73万
  • 财政年份:
    2022
  • 负责人:
    Eric Meffre
  • 依托单位:
Impact of regulatory T cells on human peripheral B cell tolerance
  • 批准号:
    8424216
  • 项目类别:
  • 资助金额:
    $20.79万
  • 财政年份:
    2012
  • 负责人:
    Eric Meffre
  • 依托单位:
Impact of regulatory T cells on human peripheral B cell tolerance
  • 批准号:
    8302578
  • 项目类别:
  • 资助金额:
    $24.88万
  • 财政年份:
    2012
  • 负责人:
    Eric Meffre
  • 依托单位:
海外基金